Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 4, 2015, Pages 4132-4137

  Fan, Yi ^a   Fan, Jin ^a   Huang, Liu ^a   Ye, Ming ^a   Huang, Zheng ^a   Wang, Yibin ^a   Li, Qiufen ^a   Huang, Jiezhen ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

miR 196a; Ovarian cancer; Overall survival; Recurrence free survival

Indexed keywords

MICRORNA; MIRN196 MICRORNA, HUMAN;

CANCER STAGING; CARCINOMA; CHI SQUARE DISTRIBUTION; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SECONDARY; TIME FACTOR; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR RECURRENCE; TUMOR VOLUME; UPREGULATION;

CARCINOMA; CELL LINE, TUMOR; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; UP-REGULATION;

EID: 84935440609     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Knutson KL, Karyampudi L, Lamichhane P and Preston C. Targeted immune therapy of ovarian cancer. Cancer Metastasis Rev 2015; 34: 53-74.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
4. Srinivasan S, Selvan ST, Archunan G, Gulyas B and Padmanabhan P. MicroRNAs -the next generation therapeutic targets in human diseases. Theranostics 2013; 3: 930-942.
5. Karunakaran D and Rayner KJ. MicroRNAs in cardiovascular health: from order to disorder. Endocrinology 2013; 154: 4000-4009.
6. Kane NM, Thrasher AJ, Angelini GD and Emanueli C. Concise review: MicroRNAs as modulators of stem cells and angiogenesis. Stem Cells 2014; 32: 1059-1066.
7. Liu H. MicroRNAs in breast cancer initiation and progression. Cell Mol Life Sci 2012; 69: 3587-3599.
8. Chen D, Cabay RJ, Jin Y, Wang A, Lu Y, Shah-Khan M and Zhou X. MicroRNA Deregulations in Head and Neck Squamous Cell Carcinomas. J Oral Maxillofac Res 2013; 4: e2.
9. Lujambio A and Lowe SW. The microcosmos of cancer. Nature 2012; 482: 347-355.
10. Song L, Liu L, Wu Z, Li Y, Ying Z, Lin C, Wu J, Hu B, Cheng SY, Li M and Li J. TGF-beta induces miR-182 to sustain NF-kappaB activation in glioma subsets. J Clin Invest 2012; 122: 3563-3578.
11. Calin GA and Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
12. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M and Croce CM. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-1801.
13. Li L, He L, Zhao J, Liu M, Li X and Tang H. miR-17-5p up-regulates YES1 to modulate the cell cycle progression and apoptosis in ovarian cancer cell lines. J Cell Biochem 2015; 116: 1050-9.
14. Feng S, Pan W, Jin Y and Zheng J. MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2. Tumour Biol 2014; 35: 12339-12344.
15. Ge T, Yin M, Yang M, Liu T and Lou G. MicroRNA-302b suppresses human epithelial ovarian cancer cell growth by targeting RUNX1. Cell Physiol Biochem 2014; 34: 2209-2220.
16. Li B, Chen H, Wu N, Zhang WJ and Shang LX. Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance. Int J Gynecol Cancer 2014; 24: 1381-1388.
17. Alonso CR. Hox proteins: sculpting body parts by activating localized cell death. Curr Biol 2002; 12: R776-778.
18. Hou T, Ou J, Zhao X, Huang X, Huang Y and Zhang Y. MicroRNA-196a promotes cervical cancer proliferation through the regulation of FOXO1 and p27Kip1. Br J Cancer 2014; 110: 1260-1268.
19. Schotte D, Chau JC, Sylvester G, Liu G, Chen C, van der Velden VH, Broekhuis MJ, Peters TC, Pieters R and den Boer ML. Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia 2009; 23: 313-322.
20. Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, Fyles T, McCready D, Wong D, Gerster K, Waldron L, Jurisica I, Penn LZ and Liu FF. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest 2009; 89: 597-606.
21. Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, Galle PR, Moehler M and Gockel I. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol 2009; 15: 2089-2096.
22. Huang F, Tang J, Zhuang X, Zhuang Y, Cheng W, Chen W, Yao H and Zhang S. MiR-196a promotes pancreatic cancer progression by targeting nuclear factor kappa-B-inhibitor alpha. PLoS One 2014; 9: e87897.
23. Zhang J, Zheng F, Yu G, Yin Y and Lu Q. miR-196a targets netrin 4 and regulates cell proliferation and migration of cervical cancer cells. Biochem Biophys Res Commun 2013; 440: 582-588.
24. Suh Y, Raulf N, Gaken J, Lawler K, Guerrero Urbano T, Bullenkamp J, Gobeil S, Huot J, Odell E and Tavassoli M. MicroRNA-196a promotes an oncogenic effect in head and neck cancer cells by suppressing annexin A1 and enhancing radioresistance. Int J Cancer 2014; [Epub ahead of print].